The present invention relates to new amino alcohol derivatives, process for the production thereof and medicaments and reagents containing these compounds.
|
##STR00007##
wherein
A is selected from the group consisting of a group nr1R2, a group nr1(CH2)pnr3R4, a group (C═NH)NH2 and a pyridinyl residue;
B is selected from the group consisting of a bond, a c1–C6 alkylene residue and a group nr5—(c2 to c6 alkylene);
D is selected from the group consisting of a c1–C6 alkylene residue and a group nr5—(c2 to c6 alkylene);
J is selected from the group consisting of piperidinediyl and piperazinediyl;
R1–R5 are each independently selected from the group consisting of hydrogen and a c1–C6 alkyl residue;
m is 1 or 2, wherein when m is 2, the two residues J are identical to or different from each other.
n and o are each independently 2, 3 or 4; and
p is 2–6,
or a physiologically tolerated salt thereof.
##STR00006##
wherein
A is selected from the group consisting of a group nr1 R2, a group nr1(CH2)pnr3R4, a group (C═NH)NH2 and a pyridinyl residue;
B and D are each independently selected from the group consisting of a bond, a c1–C6 alkylene residue, and a group nr5—(c2 to c6 alkylene);
J is selected from the group consisting of piperidinediyl and piperazinediyl;
W and X are each independently selected from the group consisting of a bond and a carbonyl group;
Y and Z are each independently a saturated or unsaturated c7–C24 hydrocarbon residue;
R1–R5 are each independently selected from the group consisting of hydrogen and a c1–C6 alkyl residue;
m is 1 or 2, wherein when m is 2, the two residues J are identical to or different from each other;
n and o are each independently 2, 3 or 4; and
p is 2–6,
or a physiologically tolerated salt thereof.
##STR00005##
wherein
A is selected from the group consisting of hydrogen, a group nr1R2, a group nr1(CH2)pnr3R4, a group (C═NH)NH2 and a pyridinyl residue;
B and D are each independently selected from the group consisting of a bond, a c1–C6 alkylene residue and a group nr5—(c2 to c6 alkylene);
J is selected from the group consisting of piperidinediyl and piperazinediyl;
W and X are each independently selected from the group consisting of a bond and a carbonyl group;
Y and Z are each independently a saturated or unsaturated c7–C24 hydrocarbon residue;
R1–R5 are each independently selected from the group consisting of hydrogen and a c1–C6 alkyl residue;
m is 0, 1 or 2, wherein when m is 2, the two residues J are identical to or different from each other;
n and o are each independently 2, 3 or 4; and
p is 2–6,
or a physiologically tolerated salt thereof,
and that m is other than 0 when A is either hydrogen or a group (C═NH)NH2 and B and D are each independently a bond or an alkylene residue, wherein the composition further comprises a therapeutic agent.
3. The composition of
7. The compound of
14. The compound of
A is NH2 or N(CH3)2;
B and D are each independently selected from the group consisting of a bond and a c1–C3 alkylene residue;
J is piperidinediyl;
m is 1;
W and X each are a carbonyl group;
Y and Z are each independently c13c17H27 or H33; and
n and o are each 2.
19. The compound of
23. The compound of
A is NH2 or N(CH3)2;
B and D are each independently selected from the group consisting of a bond and a c1–C3 alkylene residue;
J is piperidenediyl;
m is 1; and
n and o are each 2.
24. A method of introducing a biologically active agent into a target cell, comprising combining the biologically active agent with a composition as claimed in
25. The method of
26. The method of
27. The method of
28. The method of
29. A method of introducing a biologically active agent into a target cell, comprising combining the biologically active agent with a compound as claimed in
30. The method of
31. The method of
32. The method of
33. The method of
|
This is a Continuation of application Ser. No. 09/147,818 filed May 12, 1999, now abandoned. The disclosure of the prior application is hereby incorporated by reference herein in its entity.
The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances.
The invention concerns pharmaceutical agents of the general formula I
##STR00001##
in which
The alkyl, alkylene and hydrocarbon residues encompassed by the meanings of B, D, Y, Z and R1 to R5 can be straight-chained or branched. A pyridinyl residue is understood as an unsubstituted pyridine or a pyridine optionally substituted several-fold with straight-chained or branched C1–C6.
Values of 1 or 2 are preferred for m. Compounds of the general formula I are just as preferred which contain more than 2 nitrogens or, if A denotes (C═NH)NH2, those that contain more than 3 nitrogens.
The invention in addition concerns new amino alcohol derivatives of the general formula I
##STR00002##
in which
Within the sense of the present invention the following meanings in compounds of formula I are preferred independently of one another. This applies to compounds as well as to medicaments that contain such compounds and likewise also to the respective therapeutic applications of these compounds.
Compounds are especially preferred which fulfill all the above-mentioned meanings simultaneously.
Compounds are especially preferred which fulfil all the above-mentioned meanings simultaneously.
The compounds of formula I have valuable pharmacological properties and in particular they can facilitate the transport of biologically active molecules into prokaryotic or eukaryotic cells. They are therefore particularly suitable for introducing proteins, nucleic acids such as e.g. DNA, cDNA, mRNA, PNA, antisense polynucleotides and therapeutically active low molecular compounds such as peptide hormones, cytostatic agents and antibiotics into target cells within or outside of the organism. The new compounds according to the invention are therefore particularly suitable for the efficient treatment of mammals by gene therapy preferably of human patients. These compounds are also suitable for the production of drug combinations in cancer therapy, antiviral therapy, infection therapy and in diseases caused by dysregulation. In contrast to viral carriers for gene constructs, non-viral gene ferries often have only a low immunogenicity. The efficiency and persistency of the gene expression mediated by non-viral gene ferries has, however, not yet been satisfactory. In addition to improving gene expression, the compounds of the general formula I have the advantage that they can be degraded relatively easily due to the C2–C4-alkyl-0 chains on the tertiary nitrogen N of formula I.
Apart from the compounds listed in the examples, the invention concerns in particular all substances which have all possible combinations of the meanings of the variables mentioned in the examples.
The process according to the invention for the production of compounds of formula I is characterized in that a compound of the general formula II
##STR00003##
in which A, B, J, D, m, n and o have the above-mentioned meaning is reacted with a compound of the general formula III and a compound of the general formula IV
##STR00004##
in which W, X, Y and Z have the above-mentioned meaning and E and G represent reactive residues,
and subsequently if desired a protecting group contained in A, B or D is cleaved-off, a hydrogen atom representing A is converted into a group (C═NH)NH2, a compound present as an acid addition salt is converted into the free base or a compound present as a base is converted by neutralization with a non-toxic acid into a physiologically tolerated salt.
The reactive residues E and G are nucleofuge groups such as for example halogen atoms, sulfonate or sulfate groups or acidic residues of activated esters, anhydrides or mixed anhydrides.
It is expedient to react compounds of formula II with compounds of formulae III and IV in an inert solvent such as an ether, for example tetrahydrofuran or an amide such as dimethylformamide or in pyridine optionally in the presence of a base such as triethylamine or ethyldiisopropylamine or an alkali alcoholate, however, the reagents of the general formulae III or IV can be used undiluted or, if W and X represent a carbonyl group, an acid such as acetic acid or trifluoroacetic acid can be used as the solvent.
Cleavage of a protecting group contained in A, B or D is carried out depending on the chemical characteristics of this group, for example by acidic or basic hydrolysis or hydrogenolysis. An acid cleavable protecting group is for example the tert.-butoxycarbonyl residue. A hydrogen atom representing A can for example be converted into an amidino group by reaction with cyanamide or pyrazol-1-carboxamidine.
The majority of the starting compounds of the general formula II are new (especially if m represents 1 or 2) and are also a subject matter of the invention. They can be produced from known starting materials by methods known in the literature.
Potential pharmacologically acceptable salts are in particular salts with non-toxic inorganic or organic acids such as for example hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, acetic acid, trifluoroacetic acid, lactic acid, citric acid, malic acid, benzoic acid, salicylic acid, malonic acid, maleic acid, succinic acid or diaminocaproic acid.
The salts are obtained in the usual manner for example by neutralizing the compounds of formula I with the corresponding acids.
In order to produce pharmaceutical preparations or transfer reagents the compounds according to the invention are combined individually or as a combination, if desired using co-lipids, with a biologically active molecule, for example a polynucleotide, in a suitable ratio and administered in vivo or in vitro in a liquid preferably aqueous, or solid preferably lyophilized form. The in vivo administration can be carried out orally, parenterally, topically, transmucosally or by introduction into a body cavity of the patient. A delayed release from a biologically degradable matrix or administration as an aerosol or inhalable powder application is also possible.
The administered dose depends on the age, health and weight of the recipient, the extent of the disease, the type of other treatments which may be carried out at the same time, the frequency of the treatments and the type of the desired effect and can be determined experimentally by a person skilled in the art.
The following compounds are preferred within the sense of the invention in addition to the substances mentioned in the examples:
2.1 ml (15 mmol) triethylamine is added to a solution of 1.35 g (5.5 mmol) 2-{(2-hydroxy-ethyl)-[3-(4-methyl-piperazin-1-yl)-prpyl]-amino}-ethanol in 30 ml tetrahydrofuran, a solution of 2.3 ml (11 mmol) decanoyl chloride in 20 ml tetrahydrofuran is added dropwise and it is heated for 20 h to reflux. After cooling it is filtered, the filtrate is concentrated by evaporation and the residue is chromatographed on silica gel. 1.28 g of the desired compound is eluted as an oil with ethyl acetate/methanol 1:1, this is dissolved in ethyl acetate and admixed with excess ethereal hydrogen chloride solution. After concentrating the solution by evaporation the precipitate is removed by filtration and 1.3 g of the title compound (42% of theory) of melting point 208–212° C. is isolated.
The 2-{(2-hydroxy-ethyl)-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-ethanol used as the starting material can be obtained as follows:
50 mg potassium iodide is added to a solution of 4.1 g (40 mmol) diethanolamine and 7.8 g (44 mmol) 3-(4-methyl-piperazin-1-yl)-propyl chloride in 40 ml dimethyl-formamide and heated for 5 h to 60° C. After concentrating in a vacuum, the residue is chromatographed on silica gel. 2.7 g (27% of theory) of the desired compound is eluted as an oil using ethyl acetate/methanol 1:1.
The title compound is obtained as an oil in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-ethanol and oleoyl chloride in a yield of 35%.
The title compound is obtained as a viscous oil in an analogous manner to that described in example 1 from 2-hydroxyethyl-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol and oleoyl chloride in a yield of 53%.
The 2-hydroxy-ethyl-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol used as the starting material can be obtained as follows:
The title compound is obtained in an analogous manner to that described in example 1 in a 51% yield as an amorphous powder of melting range 100–120° C. from 2-[(2-hydroxy-ethyl)-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an amorphous powder in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol and dodecanoyl chloride in a yield of 48%.
The title compound is obtained as an oil in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl-methyl)-amino]-ethanol and oleoyl chloride in a yield of 37%.
The 2-hydroxyethyl-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl-methyl)-amino]-ethanol and tetradecanoyl chloride in an 86% yield.
The title compound is obtained as an oil in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl-methyl)-amino]-ethanol and dodecanoyl chloride in an 81% yield.
The title compound is obtained as an oil in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(3-piperidin-1-yl-propyl)-amino]-ethanol (J. Organomet. Chem. 251, 289 (1983)) and oleoyl chloride in a 39% yield.
1.0 g (5 mmol) dodecanoyl chloride is added dropwise to a solution of 0.7 g (2 mmol) 2-{[3-(4-amino-piperidin-1-yl)-propyl]-2-hydroxy-ethyl)-amino}-ethanol-hydrochloride in 10 ml trifluoroacetic acid and it is stirred for 18 h at room temperature. It is concentrated by evaporation, admixed with 10 ml cold 1 N sodium hydroxide solution, extracted with ethyl acetate, concentrated by evaporation and chromatographed on silica gel. 0.87 g (71% of theory) of the desired compound is eluted as an oil with ethyl acetate/methanol 4:1.
The 2-{[3-(4-amino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol-hydrochloride used as the starting material can be obtained as follows:
The title compound is obtained as an oil in a 64% yield in an analogous manner to that described in example 10 from 2-{[3-(4-amino-piperidin-1-yl)-propyl-(2-hydroxy-ethyl)-amino}-ethanol-hydrochloride and tetradecanoyl chloride.
3.1 ml (9.5 mmol) oleoyl chloride is added to a solution of 0.95 g (3.8 mmol) 2-[(2-hydroxy-ethyl)-(2-piperidin-4-yl-ethyl)-amino]-ethanol-hydrochloride in 20 ml dimethylformamide and heated for 4 h to 50° C. It is concentrated by evaporation and chromatographed on silica gel. 0.4 g (14% of theory) of the title compound is eluted as an oil with ethyl acetate/methanol 9:1.
The 2-[(2-hydroxy-ethyl)-(2-piperidin-4-yl-ethyl)-amino]-ethanol used as a starting material can be obtained as follows:
1.0 g activated ruthenium oxide is added to a solution of 57 g (0.27 mol) 2-[(2-hydroxy-ethyl)-(2-pyridin-4-yl-ethyl)-amino]-ethanol (Chem. Abstr. 1960, 13129) in 700 ml methanol and hydrogenated for 16 h at 100° C. and 150 bar hydrogen pressure. It is filtered, concentrated by evaporation and chromatographed on silica gel. 47.9 g (82% of theory) of the desired compound is eluted as an oil with methanol.
The title compound is obtained as an oil in a 71% yield in an analogous manner to that described in example 10 from 2-[(2-hydroxy-ethyl)-(2-piperidin-4-yl-ethyl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 90% yield in an analogous manner to that described in example 10 from 2-[(2-hydroxy-ethyl)-(2-piperidin-4-yl-ethyl)-amino]-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 95% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[2-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-ethyl]-amino}-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 65% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[2-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-ethyl]-amino}-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 35% yield in an analogous manner to that described in example 10 from 2-[(2-hydroxy-ethyl)-[1,4′]bipiperidinyl-4-yl-amino]-ethanol and tetradecanoyl chloride.
The 2-[(2-hydroxy-ethyl)-[1,4′]bipiperidinyl-4-yl-amino]-ethanol used as a starting material can be obtained as follows:
24 g (90 mmol) of the 2-[2-hydroxy-ethyl-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-amino]-ethanol described under 3c) is hydrogenated on ruthenium oxide analogously to the process described in example 12.17 g (70% of theory) of the desired compound is isolated as an oil.
The title compound is obtained as an oil in a 32% yield in an analogous manner to that described in example 10 from 2-[(2-hydroxy-ethyl)-[1,4′]bipiperidinyl-4-yl-amino]-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 57% yield in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-[2-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-yl)-ethyl]-amino}-ethanol and oleoyl chloride.
The title compound is obtained as an oil in a 37% yield in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(1′-methyl-[l,4′]bipiperidinyl-4-yl)-amino]-ethanol and oleoyl chloride.
The 2-[(2-hydroxy-ethyl)-(1′-methyl-[1,4′]bipiperidinyl-4-yl)-amino)-ethanol used as a starting material can be obtained as follows:
The title compound is obtained as an oil in a 37% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl]-amino}-ethanol and dodecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl]-amino}-ethanol used as a starting material can be obtained as follows:
The title compound is obtained as an oil in a 34% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl]-amino}-ethanol and tetradecanoyl chloride.
The title compound-is obtained as an oil in a 44% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol and dodecanoyl chloride.
The starting material used can be obtained from the compound of example 6b) by reaction with acrylonitrile analogously to example 21a) and subsequent hydrogenation analogously to example 21b).
The title compound is obtained as an oil in a 38% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 29% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[3-(3,4,5,6-tetrahydro-2H-[1,4′3bipyridinyl-4-ylamino)-propyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[3-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-ylamino)-propyl]-amino}-ethanol used as a starting material can be obtained as follows:
The title compound is obtained as an oil in a 34% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[3-(3,4,5,6-tetrahydro-2H-[1,4′]bipyridinyl-4-ylamino)-propyl]-amino}-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 23% yield an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-[1′-(3-dimethylamino-propyl)-[1,4′]bipiperidinyl-4-yl]-amino}-ethanol and oleoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1′-(3-dimethylamino-propyl)-[1,4′]bipiperidinyl-4-yl]-amino}-ethanol used as the starting material can be obtained as follows:
A mixture of 4.05 g (15 mmol) of the 2-[(2-hydroxy-ethyl)-[1,4′]bipiperidinyl-4-yl-amino]-ethanol described in example 17, 2.0 g potassium-carbonate, 2.2 g 3-dimethylamino-propyl chloride and 25 ml n-propanol is refluxed for 5 h, cooled, filtered and the filtrated is concentrated by evaporation. It is chromatographed on silica gel and 2.0 g (37% of theory) of the desired compound is eluted as an oil with ethyl acetate/methanolic ammonia 1:1.
The title compound is obtained as an oil in a 65% yield in an analogous manner to that described in example 1 from 2-{[3-(4-dimethylamino-piperidin-1-yl)-propyl)-(2-hydroxy-ethyl)-amino}-ethanol and oleoyl chloride.
The 2-{[3-(4-dimethylamino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as a starting material can be obtained as follows:
The title compound is obtained as an oil in a 24% yield in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl]-amino}-ethanol and oleoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl]-amino}-ethanol used as the starting material can be obtained as follows:
A mixture of 5.84 g (30 mmol) of the 2-[(2-hydroxy-ethyl)-(piperidin-4-yl)-amino]-ethanol described under 3b), 4.0 g (33 mmol) 3-dimethylamino-propyl chloride, 2.5 g potassium carbonate and 20 ml n-propanol is refluxed for 5 h, filtered, concentrated by evaporation and chromatographed on silica gel. 4.4 g (54% of theory) of the desired compound is eluted as an oil with ethyl acetate/methanolic ammonia 1:1.
A suspension of 4.5 g (4 mmol) of the 2-{[3-(4-amino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol-hydrochloride described in example 10 in 100 ml dichloromethane is admixed with 3.5 g N-ethyl-diisopropylamine and 0.87 g (4 mmol) pyrocarbonic acid di-t-butyl ester, it is refluxed for 18 h, a solution of 2.4 g (8 mmol) oleoyl chloride in 40 ml dichloromethane is added dropwise, it is refluxed for 18 h, admixed with 15 ml etheric hydrogen chloride solution and stirred for 6 h at room temperature. It is concentrated by evaporation, adjusted to pH 9 with N sodium hydroxide solution, extracted with dichloromethane and methanol, dried and concentrated by evaporation. After chromatography on silica gel (eluting agent ethyl acetate/methanol 1:1) 1.1 g (36% of theory) of the title compound is isolated as an oil.
The title compound is obtained as an oil in a 28% yield in an analogous manner to that described in example 30 from 2-{[3-(4-amino-methyl-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino }-ethanol and oleoyl chloride.
The 2-{[3-(4-aminomethyl-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained from 4-aminomethyl-piperidine analogously to the compound described under 28c.
The title compound is obtained as an oil in a 22% yield in an analogous manner to that described in example 1 from 2-[(2-hydroxy-ethyl)-(1′-ethyl-[1,4′]bipiperidinyl-4-yl)-amino]-ethanol and oleoyl chloride.
The 2-[(2-hydroxy-ethyl)-(1′-ethyl-[1,4′]bipiperidinyl-4-yl)-amino]-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in a 25% yield in an analogous manner to that described in example 30 from 2-{(2-hydroxy-ethyl)-[1-(3-amino-propyl)-piperidin-4-yl]-amino}-ethanol (example 21b) and oleoyl chloride.
The title compound is obtained as an oil in a 31% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol used as the starting material can be obtained as follows:
2-{(2-Hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol is obtained as an oil in a 29% yield analogously to the process described in example 27 by alkylation of the compound described in example 6b) with 3-dimethylamino-propyl chloride.
The title compound is obtained as an oil in a 26% yield in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl-methyl]-amino}-ethanol and oleoyl chloride.
Tetradecanoic acid-2-{(2-tetradecanoyloxy-ethyl)-2-[[1-(3-amino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethyl ester
The title compound is obtained as an oil in a 44% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-2-[[1-[3-amino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-2-[[1-(3-amino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol used as the starting material can be obtained analogously to the reaction procedure described in examples 21a) and 21b) from acrylonitrile and the precursor of example 12 (yield 47%)
The title compound is obtained as an oil in a 61% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-2-[[1-(3-amino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 50% yield in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-2-[[1-(3-dimethylamino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-2-[[1-(3-dimethylamino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol used as the starting material can be obtained in a 66% yield from the precursor of example 12 and 3-dimethylamino-propyl chloride analogously to the precursor of example 27.
The title compound is obtained as an oil in a 41% yield in an analogous manner to that described in example 1 from 2-{(2-hydroxy-ethyl)-2-[[1-(3-dimethylamino-propyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and oleoyl chloride.
32% of the theoretical yield of the title compound is obtained as an oil in an analogous manner to that described in example 10 from 2-{[3-(4-(2-amino-ethyl)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and tetradecanoyl chloride.
The 2-{[3-(4-(2-amino-ethyl)-piperidin-1-yl]-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in 35% of the theoretical yield in an analogous manner to that described in example 10 from 2-{[3-(4-(2-amino-ethyl)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in 18% of the theoretical yield in an analogous manner to that described in example 10 from 2-{[3-(4-(3-amino-propylamino)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and dodecanoyl chloride.
The 2-{[3-(4-(3-amino-propylamino)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained as follows:
Reaction of the 2-{[3-(4-amino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol described in example 10 with acrylonitrile analogously-to example 21a) and subsequent hydrogenation analogously to example 21b) yields the desired compound as an oil.
The title compound is obtained as an oil in 12% of the theoretical yield in an analogous manner to that described in example 10 from 2-{[3-(4-(3-amino-propylamino)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and tetradecanoyl chloride.
A mixture of 1.92 g (3 mmol) of the compound from example 13, 0.25 g cyanamide and 5 ml n-butanol is heated for 2 h to 120° C., cooled, the residue is taken up in dichloromethane, washed with a small amount of water, dried and concentrated by evaporation. After chromatography on silica gel 0.96 g (47% of theory) of the title compound is eluted as a wax with ethyl acetate/methanol 1:1.
The title compound is obtained as an oil in a 64% yield in an analogous manner to that described in example 44 from the compound of example 36 and cyanamide.
The title compound is obtained as an oil in a 36% yield in an analogous manner to that described in example 1 from 2-[(2-ethylamino-ethyl)-(2-hydroxy-ethyl)-amino]-ethanol and oleoyl chloride.
The 2-[(2-ethylamino-ethyl)-(2-hydroxy-ethyl)-amino]-ethanol used as the starting material can be obtained as follows:
11.0 g (58 mmol) N-{2-[bis-(2-hydroxy-ethyl)-amino]-ethyl}-acetamide (J. Med. Chem. 36, 1839 (1993)) is reduced analogously to example 20b). 8.3 g (81% of theory) of the desired compound is isolated as an oil.
The title compound is obtained as an oil in a 44% yield in an analogous manner to that described in example 12 from 2-[(2-diethylamino-ethyl)-(2-hydroxy-ethyl)-amino]-ethanol and oleoyl chloride.
The title compound is obtained as an oil in a 25% yield in an analogous manner to that described in example 12 from 2-[(2-amino-ethyl)-(2-hydroxy-ethyl)-amino]-ethanol (J. Am. Chem. Soc. 81, 3984 (1959)) and oleoyl chloride.
The title compound is obtained as an oil in a 29% yield in an analogous manner to that described in example 12 from 2-{[3-(3-amino-propylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and oleoyl chloride.
The 2-{[3-(3-amino-propylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained by reaction of 2-[3-amino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol (J. Am. Chem. Soc. 66, 728 (1944)) with acrylonitrile analogously to example 21a) and subsequentl hydrogenation analogously to example 21b). b.p.0.06 176–177° C.
The title compound is obtained as an oil in a 65% yield in an analogous manner to that described in example 1 from 2-[(3-dimethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol and oleoyl chloride.
The 2-[(3-dimethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol used as the starting material can be obtained analogously to the procedure of example 27 from diethanolamine and 3-dimethylamino-propyl chloride. b.p.1.5 135–136° C.
The title compound is obtained as an oil in a 65% yield in an analogous manner to that described in example 1 from 2-[(3-diethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol (Chem. Pharm. Bull. 9, 313 (1961)) and oleoyl chloride.
The title compound is obtained as an oil in a 78% yield in an analogous manner to that described in example 1 from 2-[(3-dimethyl-amino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 79% yield in an analogous manner to that described in example 1 from 2-[(3-dimethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 50% yield in an analogous manner to that described in example 1 from 2-[(3-diethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 60% yield in an analogous manner to that described in example 1 from 2-[(3-diethylamino-propyl)-(2-hydroxy-ethyl)-amino]-ethanol and dodecanoyl chloride.
The title compound is obtained as an oil in a 63% yield in an analogous manner to that described in example 1 from 2-[{3-[(3-dimethylamino-propyl)-methyl-amino)-propyl}-(2-hydroxy-ethyl)-amino]-ethanol and oleoyl chloride.
The 2-[{3-[(3-dimethylamino-propyl)-methyl-amino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol used as the starting material can be obtained analogously to example 28c) by alkylation of N,N,N′-trimethyl-propane-1,3-diamine (J. Chem. Soc. (C) 1966, 527) with N-(3-chloro-propyl)-diethanolamine.
The title compound is obtained as an oil in a 59% yield in an analogous manner to that described in example 1 from 2-[{3-[(3-diethylamino-propyl)-methyl-amino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol and oleoyl chloride.
The 2-[{3-[(3-diethylamino-propyl)-methyl-amino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol used as the starting material can be obtained analogously to the precursor described in example-56 by alkylation of N,N-diethyl-N′-methyl-propane-1,3-diamine (“Monatsh. Chem. 112, 825 (1981)) with N-(3-chloro-propyl)-diethanolamine.
The title compound is obtained as a wax in a 31% yield in an analogous manner to that described in example 10 from 2-{[4-(3-amino-propylamino)-butyl]-(2-hydroxy-ethyl)-amino}-ethanol and dodecanoyl chloride.
The 2-{[4-(3-amino-propylamino)-butyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained 2-[(4-amino-butyl)-(2-hydroxy-ethyl)-amino]-ethanol (J. Am. Chem. Soc. 81, 3984 (1959)) and acrylo-nitrile analogously to example 21a) and subsequent hydrogenation analogously to example 21b).
The title compound with a melting point of 245–246° C. is obtained in a 49% yield in an analogous manner to that described in example 10 from 2-{[3-(3-amino-propylamino)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol (see example 49) and dodecanoyl chloride.
The title compound is obtained as an oil in a 27% yield in an analogous manner to that described in example 10 from 2-{[4-(3-amino-propylamino)-butyl]-(2-hydroxy-ethyl)-amino}-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 35% yield in an analogous manner to that described in example 1 from 2-[{3-[(3-dimethylamino-propyl)-methyl-amino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 61% yield in an analogous manner to that described in example 1 from 2-[{3-[(3-diethylamino-propyl)-methyl-amino]-propyl}-(2-hydroxy-ethyl)-amino]-ethanol and tetradecanoyl chloride.
The title compound is obtained as an oil in a 91% yield in an analogous manner to that described in example 44 from the compound of example 22 and cyanamide.
The title compound is obtained as an oil in an 82% yield in an analogous manner to that described in example 44 from the compound of example 24 and cyanamide.
The title compound is obtained as an oil in a 94% yield in an analogous manner to that described in example 44 from the compound of example 40 and cyanamide.
The title compound is obtained as an oil in a 38% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(2-amino-ethyl)-piperidin-4-yl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(2-amino-ethyl)-piperidin-4-yl]-amino}-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in a 29% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(2-amino-ethyl)-piperidin-4-yl-methyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(2-amino-ethyl)-piperidin-4-yl-methyl]-amino}-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in a 27% yield in an analogous manner to that described in example 10 from 2-{[3-(4-(aminomethyl)-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and tetradecanoyl chloride.
The 2-{[3-(4-aminomethyl-piperiain-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material can be obtained analogously to the compound described in example 28c from 4-aminomethyl-piperidine.
The title compound is obtained as an oil in a 25% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(3-dimethylamino-propyl)-piperidin-4-yl]-amino}-ethanol used as the starting material is described in example 29.
The title compound is obtained as an oil in a 62% yield in an analogous manner to that described in example 10 from 2-{[3-(4-dimethylamino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol and tetradecanoyl chloride.
The 2-{[3-(4-dimethylamino-piperidin-1-yl)-propyl]-(2-hydroxy-ethyl)-amino}-ethanol used as the starting material is described in example 28.
The title compound is obtained as an oil in a 22% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(4-amino-butyl)-piperidin-4-yl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(4-amino-butyl)-piperidin-4-yl]-amino}-ethanol used as the starting material can be obtained as follows:
The title compound is obtained as an oil in a 23% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(4-dimethylamino-butyl)-piperidin-4-yl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(4-dimethylamino-butyl)-piperidin-4-yl]-amino}-ethanol used as the starting material can be obtained as follows:
4.7 ml formic acid and 5.6 ml saturated Formalin solution are added dropwise at 0° C. to 6.5 g (25 mmol) 2-{(2-hydroxy-ethyl)-[1-(4-amino-butyl)-piperidin-4-yl]-amino}-ethanol (example 71b) it is heated to 95–100° C. and stirred for a further 9 h. It is allowed to cool, admixed with 6.5 ml concentrated hydrochloric acid, refluxed for 3 h, made strongly alkaline with 10 N sodium hydroxide solution and extracted with dichloromethane. After drying and concentrating the extract by evaporation, 6.0 g (84% of theory) of the desired compound remain as an oil.
The title compound is obtained as an oil in a 33% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(4-amino-butyl)-piperidin-4-yl-methyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(4-amino-butyl)-piperidin-4-yl-methyl]-amino}-ethanol used as the starting material can be obtained as follows:
The desired compound is obtained as an oil by reacting 2-[(2-hydroxy-ethyl)-(piperidin-4-yl-methyl)-amino]-ethanol (example 6b) with 4-bromo-butyronitrile analogously to example 71b) and subsequently hydrogenating analogously to example 71b).
The title compound is obtained as an oil in a 43% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-[1-(4-dimethylamino-butyl)-piperidin-4-yl-methyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-[1-(4-dimethylamino-butyl)-piperidin-4-yl-methyl]-amino}-ethanol used as the starting material can be obtained (yield 69% of theory) from the 2-{(2-hydroxy-ethyl)-1-(4-amino-butyl)-piperidin-4-yl-methyl]-amino}-ethanol described under example 73 by the method described in example 72 by reaction with formic acid and Formalin solution.
The title compound is obtained as an oil in a 17% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl)-2-[[1-(4-amino-butyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-2-[[1-(4-amino-butyl)-piperidin-4-yl]-ethyl]-amino}-ethanol used as the starting material can be obtained as follows:
The desired compound is obtained as an oil by reacting the 2-[(2-hydroxy-ethyl)-(2-piperidin-4-yl-ethyl)-amino]-ethanol described in example 12 with 4-bromo-butyronitrile analogously to example 71a) and subsequently hydrogenating analogously to example 71b).
The title compound is obtained as an oil in a 33% yield in an analogous manner to that described in example 10 from 2-{(2-hydroxy-ethyl) -2-[[1-(4-dimethylamino-butyl)-piperidin-4-yl]-ethyl]-amino}-ethanol and tetradecanoyl chloride.
The 2-{(2-hydroxy-ethyl)-2-[[1-(4-dimethylamino-butyl) -piperidin-4-yl]-ethyl]-amino}-ethanol used as the starting material can be obtained (yield 72% of theory) from the 2-{(2-hydroxy-ethyl)-2-[[1-(4-amino-butyl)-piperidin-4-yl]-ethyl]-amino}-ethanol described in example 75 by reaction with formic acid and Formalin solution according to the method described in example 72.
1. Test Principle
The testing of DOTAP or the compounds of the invention comprises transfection of the test cells, protein determination by means of the BCA method (Pierce) and carrying out a CAT Elisa and these are described here using DOTAP (Boehringer Mannheim) as an example. After ultrasonication the cationic lipid DOTAP forms unilamellar vesicles (liposomes) in aqueous solution which spontaneously form stable complexes with the DNA (pCMV-CAT). These complexes adhere to the cell surface, fuse with the cell membrane and pCMV-CAT is released into the cytoplasm. The transiently expressed CAT is detected in the cell lysate.
1.1 Test Cells
HeLa, human cancer epithelial cell line from the cervix, ATCC CCL 2
RPMI 1640, human cancer epithelial cell line from the nasal septum, ATCC CCL 30
CALU 1, human cancer epithelial cell line from the lung, ECACC 93120818 or another suitable test cell line
1.2 Test Medium
The composition of the test medium used for the respective cell line corresponds with that of the respective culture medium, only the content of FCS is reduced by 50% (only 5% FCS instead of 10%).
2. Determination Procedure
2.1 Feeding Cells for the Test
The DOTAP/DNA complexes are mixed in a sterile 96-well round-bottom plate.
60 μl HBS (Hank's buffered saline) buffer is added first, then 20 μl DOTAP is added. The DNA is diluted 1:20 with HBS. Then 40 μl=2 μg DNA is added to the transfection mixtures and mixed thoroughly. The mixture is allowed to stand for 15 min at room temperature.
Procedure for Transfection:
The CAT (chloroamphenicol acetyl transferase)-Elisa serves to quantitatively determine the CAT expression in eukaryotic cells after transfection with a plasmid that contains CAT as the reporter gene. The CAT-Elisa is a sandwich enzyme immunoassay. Anti-CAT antibodies are bound adsorptively to the walls of the modules. In the first step CAT from cell extracts specifically binds to the coated modules. In the second step the fixed CAT is bound by an ANTI-CAT antibody which is labelled with digoxigenin (anti-CAT-DIG). Anti-CAT-DIG is detected in the third step by a peroxidase-labelled antibody against digoxigenin (Anti-DIG-POD) and visualized in a subsequent substrate reaction.
Procedure:
The working steps of the CAT-Elisa are carried out according to the working instructions contained in the kit.
The microtitre plate is measured at 405 nm and a reference wavelength of 492 nm with an Elisa reader.
The pharmacological data are shown as an example in the following table:
relative transfection efficiency in a CAT-Assay (DOTAP = 1)
compound of example
HeLa cells
Calu cells
34
3.2
3.9
60
3.2
3.4
Dimoudis, Nikolaos, Friebe, Walter-Gunar, Knipp, Bernhard, Michaelis, Uwe
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 3689494, | |||
| 5491263, | Dec 21 1993 | The Dow Chemical Company | Aminoethylation process for production of substituted ethylene diamines |
| 5635487, | Dec 29 1994 | BUDKER, TATYANA | Amphipathic, micellar delivery systems for biologically active polyions |
| EP2901, | |||
| JP5232660, | |||
| JP63025654, | |||
| WO9405624, | |||
| WO9525542, | |||
| WO9617823, | |||
| WO9700241, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jan 31 2002 | MediGene Oncology GmbH | (assignment on the face of the patent) | / | |||
| Oct 14 2003 | Roche Diagnostics GmbH | FRIEBE, WALTER-GUNAR | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016875 | /0919 | |
| Oct 14 2003 | Roche Diagnostics GmbH | DIMOUDIS, NIKOLAOS | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016875 | /0919 | |
| Oct 14 2003 | Roche Diagnostics GmbH | MICHAELIS, UWE | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016875 | /0919 | |
| Oct 14 2003 | Roche Diagnostics GmbH | KNIPP, BERNHARD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016875 | /0919 | |
| Nov 19 2004 | MICHAELIS, UWE WEILHELM | MediGene Oncology GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016898 | /0364 | |
| Dec 12 2004 | FRIEBE, WALTER-GUNAR MANNHEIM | MediGene Oncology GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016898 | /0364 | |
| Dec 23 2004 | DIMOUDIS, NIKOLAOS WIELENBACH | MediGene Oncology GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016898 | /0364 | |
| Jan 10 2005 | KNIPP, BERNHARD KURTEN | MediGene Oncology GmbH | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 016898 | /0364 | |
| Aug 11 2005 | MediGene Oncology GmbH | Medigene AG | MERGER SEE DOCUMENT FOR DETAILS | 017594 | /0776 |
| Date | Maintenance Fee Events |
| Mar 01 2010 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Apr 11 2014 | REM: Maintenance Fee Reminder Mailed. |
| Aug 29 2014 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Aug 29 2009 | 4 years fee payment window open |
| Mar 01 2010 | 6 months grace period start (w surcharge) |
| Aug 29 2010 | patent expiry (for year 4) |
| Aug 29 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 29 2013 | 8 years fee payment window open |
| Mar 01 2014 | 6 months grace period start (w surcharge) |
| Aug 29 2014 | patent expiry (for year 8) |
| Aug 29 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 29 2017 | 12 years fee payment window open |
| Mar 01 2018 | 6 months grace period start (w surcharge) |
| Aug 29 2018 | patent expiry (for year 12) |
| Aug 29 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |